- Home
- HOWL vs MAIA Comparison
HOWL vs MAIA Comparison
Compare HOWL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOWL
- MAIA
- Stock Information
- Founded
- HOWL 2017
- MAIA 2018
- Country
- HOWL United States
- MAIA United States
- Employees
- HOWL N/A
- MAIA N/A
- Industry
- HOWL Biotechnology: Pharmaceutical Preparations
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- HOWL Health Care
- MAIA Health Care
- Exchange
- HOWL Nasdaq
- MAIA Nasdaq
- Market Cap
- HOWL 37.9M
- MAIA 46.7M
- IPO Year
- HOWL 2021
- MAIA 2022
- Fundamental
- Price
- HOWL $0.87
- MAIA $1.96
- Analyst Decision
- HOWL Strong Buy
- MAIA
- Analyst Count
- HOWL 3
- MAIA 0
- Target Price
- HOWL $9.00
- MAIA N/A
- AVG Volume (30 Days)
- HOWL 232.7K
- MAIA 319.8K
- Earning Date
- HOWL 05-08-2025
- MAIA 05-20-2025
- Dividend Yield
- HOWL N/A
- MAIA N/A
- EPS Growth
- HOWL N/A
- MAIA N/A
- EPS
- HOWL N/A
- MAIA N/A
- Revenue
- HOWL $1,143,000.00
- MAIA N/A
- Revenue This Year
- HOWL N/A
- MAIA N/A
- Revenue Next Year
- HOWL $733.33
- MAIA N/A
- P/E Ratio
- HOWL N/A
- MAIA N/A
- Revenue Growth
- HOWL N/A
- MAIA N/A
- 52 Week Low
- HOWL $0.60
- MAIA $1.40
- 52 Week High
- HOWL $6.34
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- HOWL 46.85
- MAIA 52.24
- Support Level
- HOWL $0.80
- MAIA $1.80
- Resistance Level
- HOWL $0.97
- MAIA $2.18
- Average True Range (ATR)
- HOWL 0.07
- MAIA 0.31
- MACD
- HOWL 0.02
- MAIA -0.01
- Stochastic Oscillator
- HOWL 41.92
- MAIA 35.00
About HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.